Here the authors show that cx 5461 a small molecule in clinical trials as rna polymerase inhibitor has g4 stablization properties and can be repurposed to target dna repair defective cancers cells. Cx 5461 is a first in class small molecule g quadruplex g4 stabiliser being developed for the treatment of haematological malignancies and solid tumours.
Senhwa Biosciences Inc Tw Ppt Download
Control Of Ribosomal Rna Transcription By Nutrients Intechopen
Cx 5461 Dna Rna Synthesis Inhibitor Read Reviews Product Use
Cx 5461 is safe at doses associated with clinical benefit and dermatologic aes are manageable.
Cx 5461 mechanism. Cx 5461 is a first in class non genotoxic small molecule targeted inhibitor of rna polymerase i pol i that activates the p53 pathway without causing dna damage. Cx 5461 is the first potent and selective inhibitor of rna pol i transcription. Cx 5461 selectively inhibits the sl1 component of rna polymerase i in the ribosome biogenesis pathway and gives potent antitumor activity in models of cancer cancer research.
Find all the information about cx 5461 for cell signaling research. Cx 5461 is a first in class selective inhibitor of rdna transcription. Cx 5461 represents a potent small molecule inhibitor of rrna synthesis that specifically inhibits the transcription driven by rna polymerase pol i and induces tumor cell death through triggering a pro death autophagy.
These drugs have distinct mechanisms of action of inhibiting rrna synthesis. Cx 5461 is a potent small molecule rrna synthesis inhibitor with an ic50 of 011 mm. Recently the rrna synthesis inhibitors cx 5461 and bmh 21 have shown therapeutic potential in different cancer models 10 13 17.
Cx 5461 is a recently discovered small molecule selective pol i inhibitor which can inhibit pol i driven rrna transcription via disrupting the recruitment of pol i to rdna promoter but does not inhibit pol ii driven messenger rna mrna synthesis or dna replication or protein translation10 several studies demonstrated that cx 5461 could inhibit the initiation stage of rrna synthesis and induce different types of programmed cell death in solid tumors and hematologic malignancies1012. Cx 5461 adisinsight either you have javascript disabled or your browser does not support javascript. Compound cx 5461 is an orally active small molecule that is in preclinical development as a broad spectrum antitumor agent.
Cx 5461 Rna Pol I Inhibitor
Three Dimensional Distribution Of Ubf And Nopp140 In Relationship To
Alternative Splicing Of Human Telomerase Reverse Transcriptase In
EmoticonEmoticon